UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA has accepted a BLA from UCB for Cimzia (certolizumab pegol) seeking an indication for rheumatoid arthritis, the Brussels, Belgium-based biotech announced Feb. 6. The filing, for monotherapy or treatment in combination with methotrexate, is slated for a standard review, giving the application an early December action date
You may also be interested in...
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.